Barcelona – December 2012 – Sagetis is pleased to announce that MINECO has granted funding to the CHAPERONES project (IPT-2012-0561-010000) – Development of pharmacological chaperones for the treatment of rare metabolic diseases.
In the consortium, led by Minoryx Therapeutics, also participates the biotechnology company Oryzon, Sagetis and PaloBiofarma, as well as research groups from the University of Barcelona and the Autonomous University of Madrid. The consortium has received 2.3M € of financing from the Ministry of Economy and Competitiveness, INNPACTO 2012 program (IPT-2012-0561-010000).
About Sagetis Biotech
At Sagetis Biotech we are devoted to developing innovative drug delivery technologies to tackle challenging unmet medical needs. Based in Barcelona, Sagetis Biotech was founded in 2010 as a spin-off from GEMAT (Materials Engineering Group) at IQS.
The company's versatile, polymeric-based platforms are designed to tackle highly challenging areas, such as (i) delivery through difficult-to-cross barriers(e.g. blood-brain barrier, intestinal mucus gel layer, ocular); (ii) efficient transfection of genetic material, using both viral and non-viral vectors.